Genetics

Glaucoma Genetics: State of the Science

The State of the Art of Glaucoma Genetics

By Heather Johnson | February 5, 2019

SAN FRANCISCO – Advances in glaucoma genetics potentially hold the key to new therapies for prevention, early detection, and a cure, researcher Janey L. Wiggs,…

Read More
Can 2019 Be ‘Transformative’ for AGTC?

After XLRS Gene Therapy Disappoints, AGTC Looks to ‘Transformative Year’

By Rich Kirkner | January 16, 2019

Since announcing disappointing clinical trial results for one of its lead ophthalmic gene therapy candidates and the termination of its collaboration agreement with Biogen, Applied…

Read More
What Relaxed Gene Therapy Oversight Means

Putting Relaxed NIH, FDA Oversight of Gene Therapies into Perspective

By Michelle Dalton | November 28, 2018

The first human gene therapy trial started in 1990, and over the course of that decade a multitude of questions about the safety and efficacy…

Read More
The Sweet Six: Recipients of the 2018 Ophthalmology Innovation Awards

The Sweet Six: Recipients of the 2018 Ophthalmology Innovation Awards

By Rich Kirkner | October 25, 2018

The first Ophthalmology Innovation Awards were presented last night at the OIS-X Gala. Here’s a rundown of the award winners. Clinical Innovator: Ike Ahmed, MD…

Read More
Gene Therapy Treatments Are Filling Some Companies’ Pipelines

Gene Therapy Treatments Are Filling Some Companies’ Pipelines

By Steve Lenier | August 15, 2018

Major pharma companies in ophthalmology aren’t the only ones making plays in the gene therapy space, as we reported last week. Mid-size and small companies…

Read More
Big Companies Keep Making Big Plays in Gene Therapy

Big Companies Keep Making Big Plays in Gene Therapy

By Steve Lenier | August 8, 2018

When Allergan and Editas Medicine disclosed this week that they would move forward on their collaboration to develop a genome editing-medicine for treatment of an…

Read More
Eye Care Plays Big at Gene and Cell Meeting

Eye Care Plays Big at Gene and Cell Meeting

By Rich Kirkner | May 23, 2018

Eye care commanded a key stage at the 21st Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) last week in Chicago.…

Read More
Takeaways from OIS@ASCRS 2018

15 Things We Learned at OIS@ASCRS

By Rich Kirkner | April 20, 2018

Here are 15 takeaways from last week’s OIS@ASCRS 2018. Barry Cheskin of PowerVision reported on a pilot study of 27 patients who had the FluidVision…

Read More
41 Things On Tap at OIS@ASCRS

41 Things On Tap at OIS@ASCRS

By Rich Kirkner | April 4, 2018

There are 41 different sessions, panels, and presentations happening at OIS@ASCRS 2018 – including five different breakout sessions on everything from dry eye to emerging…

Read More
Emerging Gene Therapy Candidate Advances

MeiraGTx Gene Therapy Candidate for Achromatopsia Moves Forward

By Steve Lenier | March 22, 2018

An emerging gene therapy candidate for the treatment of inherited eye disease has taken a step forward with MeiraGTx announcing that it has received Priority…

Read More
Handicapping the Entries in the Geographic Atrophy Space

Handicapping the Entries in the Geographic Atrophy Space

By Rich Kirkner | September 28, 2017

The race to find an effective treatment for geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD) for which no approved treatment exists,…

Read More
Can Ocular Therapies Diversify Biogen Portfolio? - Eye On Innovation Article - Healthegy

Can Ocular Therapies Diversify Biogen Portfolio?

By Michelle Dalton | June 29, 2016

Biotechnology company Biogen (Cambridge, MA) recently committed $20 million into a collaboration with the University of Pennsylvania to co-develop gene therapies using next-generation adeno-associated virus…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.